Grace Huang1, Karol Pencina1, Zhuoying Li1, Caroline M Apovian2, Thomas G Travison3, Thomas W Storer1, Thiago Gagliano-Jucá1, Shehzad Basaria1, Shalender Bhasin1. 1. Department of Medicine, Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital, Boston, Massachusetts, USA. 2. Department of Medicine, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center, Massachusetts, USA. 3. Department of Medicine, Institute for Aging Research, Hebrew SeniorLife, Division of Gerontology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Abstract
BACKGROUND: It remains controversial whether high protein diets improve cardiometabolic profile. We investigated whether increasing protein intake to 1.3 g/kg/day in functionally limited older adults with usual protein intake ≤RDA (0.8 g/kg/day) improves visceral fat accumulation and serum cardiovascular risk markers more than the recommended daily allowance (RDA). METHODS: The Optimizing Protein Intake in Older Men Trial was a placebo-controlled, randomized trial in which 92 functionally limited men, ≥65 years, with usual protein intake ≤RDA were randomized for 6 months to: 0.8 g/kg/day protein plus placebo; 1.3 g/kg/day protein plus placebo; 0.8 g/kg/day protein plus testosterone enanthate 100 mg weekly; or 1.3 g/kg/day protein plus testosterone enanthate 100 mg weekly. In this substudy, metabolic and inflammatory serum markers were measured in 77 men, and visceral adipose tissue (VAT) was assessed using dual-energy x-ray absorptiometry in 56 men. RESULTS: Treatment groups were similar in their baseline characteristics. Randomization to 1.3 g/kg/day protein group was associated with greater reduction in VAT compared to 0.8 g/kg/day group (between-group difference: -17.3 cm2, 95% confidence interval [CI]: -29.7 to -4.8 cm2, p = .008), regardless of whether they received testosterone or placebo. Changes in fasting glucose, fasting insulin, HOMA-IR, leptin, adiponectin, IL-6, and hs-CRP did not differ between the 0.8 versus 1.3 g/kg/day protein groups regardless of testosterone use. CONCLUSIONS: Protein intake >RDA decreased VAT in functionally limited older men but did not improve cardiovascular disease risk markers. CLINICAL TRIALS REGISTRATION NUMBER: NCT01275365.
BACKGROUND: It remains controversial whether high protein diets improve cardiometabolic profile. We investigated whether increasing protein intake to 1.3 g/kg/day in functionally limited older adults with usual protein intake ≤RDA (0.8 g/kg/day) improves visceral fat accumulation and serum cardiovascular risk markers more than the recommended daily allowance (RDA). METHODS: The Optimizing Protein Intake in Older Men Trial was a placebo-controlled, randomized trial in which 92 functionally limited men, ≥65 years, with usual protein intake ≤RDA were randomized for 6 months to: 0.8 g/kg/day protein plus placebo; 1.3 g/kg/day protein plus placebo; 0.8 g/kg/day protein plus testosterone enanthate 100 mg weekly; or 1.3 g/kg/day protein plus testosterone enanthate 100 mg weekly. In this substudy, metabolic and inflammatory serum markers were measured in 77 men, and visceral adipose tissue (VAT) was assessed using dual-energy x-ray absorptiometry in 56 men. RESULTS: Treatment groups were similar in their baseline characteristics. Randomization to 1.3 g/kg/day protein group was associated with greater reduction in VAT compared to 0.8 g/kg/day group (between-group difference: -17.3 cm2, 95% confidence interval [CI]: -29.7 to -4.8 cm2, p = .008), regardless of whether they received testosterone or placebo. Changes in fasting glucose, fasting insulin, HOMA-IR, leptin, adiponectin, IL-6, and hs-CRP did not differ between the 0.8 versus 1.3 g/kg/day protein groups regardless of testosterone use. CONCLUSIONS: Protein intake >RDA decreased VAT in functionally limited older men but did not improve cardiovascular disease risk markers. CLINICAL TRIALS REGISTRATION NUMBER: NCT01275365.
Authors: Shalender Bhasin; Caroline M Apovian; Thomas G Travison; Karol Pencina; Lynn L Moore; Grace Huang; Wayne W Campbell; Zhuoying Li; Andrew S Howland; Ruo Chen; Philip E Knapp; Martha R Singer; Mitali Shah; Kristina Secinaro; Richard V Eder; Kathleen Hally; Haley Schram; Richelle Bearup; Yusnie M Beleva; Ashley C McCarthy; Erin Woodbury; Jennifer McKinnon; Geeta Fleck; Thomas W Storer; Shehzad Basaria Journal: JAMA Intern Med Date: 2018-04-01 Impact factor: 21.873
Authors: S Bhasin; L Woodhouse; R Casaburi; A B Singh; D Bhasin; N Berman; X Chen; K E Yarasheski; L Magliano; C Dzekov; J Dzekov; R Bross; J Phillips; I Sinha-Hikim; R Shen; T W Storer Journal: Am J Physiol Endocrinol Metab Date: 2001-12 Impact factor: 4.310
Authors: Nicolaas E P Deutz; Jürgen M Bauer; Rocco Barazzoni; Gianni Biolo; Yves Boirie; Anja Bosy-Westphal; Tommy Cederholm; Alfonso Cruz-Jentoft; Zeljko Krznariç; K Sreekumaran Nair; Pierre Singer; Daniel Teta; Kevin Tipton; Philip C Calder Journal: Clin Nutr Date: 2014-04-24 Impact factor: 7.324
Authors: Wayne W Campbell; Jung Eun Kim; Akua F Amankwaah; Susannah L Gordon; Eileen M Weinheimer-Haus Journal: J Nutr Date: 2015-08-05 Impact factor: 4.798
Authors: N Santesso; E A Akl; M Bianchi; A Mente; R Mustafa; D Heels-Ansdell; H J Schünemann Journal: Eur J Clin Nutr Date: 2012-04-18 Impact factor: 4.016